Aspen Pharmacare

Aspen Pharmacare

APN.JOPre-clinical
Founded 1988aspenpharma.com

Aspen Pharmacare is a leading South African multinational pharmaceutical company with a vast global footprint, improving patient health in over 115 countries through high-quality, affordable medicines. The company operates through two key business segments: Manufacturing and Commercial Pharmaceuticals, with a diverse portfolio covering sterile injectables, oral solid doses, liquids, semi-solids, biologicals, and active pharmaceutical ingredients (APIs). With a strong leadership team and a commitment to integrity and innovation, Aspen holds manufacturing approvals from stringent global regulatory agencies like the US FDA, positioning it as a significant player in the global generics and specialty pharma market.

Market Cap
$58.3B
Founded
1988
Employees
9,300-9,500
Focus
Small Molecules

APN.JO · Stock Price

USD 13141.006764.00 (-33.98%)

Historical price data

AI Company Overview

Aspen Pharmacare is a leading South African multinational pharmaceutical company with a vast global footprint, improving patient health in over 115 countries through high-quality, affordable medicines. The company operates through two key business segments: Manufacturing and Commercial Pharmaceuticals, with a diverse portfolio covering sterile injectables, oral solid doses, liquids, semi-solids, biologicals, and active pharmaceutical ingredients (APIs). With a strong leadership team and a commitment to integrity and innovation, Aspen holds manufacturing approvals from stringent global regulatory agencies like the US FDA, positioning it as a significant player in the global generics and specialty pharma market.

Technology Platform

Global integrated manufacturing platform for sterile injectables, oral solid doses, liquids, semi-solids, biologicals, and active pharmaceutical ingredients (APIs), with approvals from top-tier regulatory agencies including the US FDA.

Funding History

1
IPOUndisclosedUndisclosedJun 15, 1997

Opportunities

Growth is driven by the sustained global demand for affordable generics and biosimilars, particularly in high-growth emerging markets where Aspen has a leading presence.
The company's FDA-approved manufacturing platform also positions it to benefit from the trend towards diversified and resilient pharmaceutical supply chains.

Risk Factors

Key risks include intense pricing pressure in the global generics market, regulatory compliance challenges across multiple jurisdictions, currency volatility, and the financial leverage remaining from the company's historical acquisition strategy.

Competitive Landscape

Aspen competes with global generics firms like Teva and Viatris, as well as specialty injectables players. Its differentiation lies in its unique dual-market footprint (developed & emerging), deep sterile manufacturing expertise, and its position as the leading pharmaceutical manufacturer in Africa.

Publications
5

Company Info

TypeTherapeutics
Founded1988
Employees9,300-9,500
LocationSouth Africa
StagePre-clinical
RevenueRevenue Generating

Trading

TickerAPN.JO
ExchangeJSE

Therapeutic Areas

AnaestheticsThrombosisOncologyAutoimmune DiseasesPediatric NutritionGeneral Medicine
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile